A Phase 2 interventional study of IFX-1 and Placebo in Hidradenitis Suppurativa (HS), sponsored by InflaRx GmbH. Completed at 41 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-04-08.
Sponsored by InflaRx GmbH · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 161 studies in Hidradenitis Suppurativa with a site in United States — 38 open to participants now, 55 under way, 12 of them phase 3. Hidradenitis Suppurativa · United States.
Among the 161 studies in Hidradenitis Suppurativa with a site in United States, this one is the 43rd largest by enrollment of the 139 interventional ones that give a count, is one of 9 that started in 2018, is one of 61 in phase 2, and was the 29th registered.
285 studies on the registry are indexed under Hidradenitis Suppurativa; 88 are open to participants now.
Browse Hidradenitis Suppurativa studies →38 of the 161 studies in Hidradenitis Suppurativa with a site in United States are open now. Recruiting first, the newest first:
Regeneron Pharmaceuticals · Sites in United States
Ages 18+
Novartis Pharmaceuticals · Sites in United States
Ages 18–65
Corvus Pharmaceuticals, Inc. · Sites in United States
Ages 18+
Harrison Dermatology · Sites in United States
Ages 12+
Beth Israel Deaconess Medical Center · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 61 Hidradenitis Suppurativa studies recruiting now, 33 (54%) set no upper age limit and 17 (28%) stop at 75 or younger; 13 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
161 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 19 · Phase 2 65 · Phase 3 27 · Phase 4 5
First in 2005; this study’s year is marked. 9 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 179 is above the median of 45 across 200 interventional studies indexed under Hidradenitis Suppurativa.
Median enrollment 45 across the 139 interventional studies, 300 across the 22 observational. Of the 95 that completed or were terminated, 52 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
87 of 161 have an industry lead sponsor. The 10 most frequent:
InflaRx GmbH is the lead sponsor of 12 studies on the registry; none are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 6 (75%) have results posted.
InflaRx GmbH has 3 studies filed under Hidradenitis Suppurativa — fewer than ten, so there is no comparison to draw.
21 of the studies in Hidradenitis Suppurativa with a site in United States that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06468228Phase 3AbbVieA Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | 2026-12 |
| NCT06921850Phase 3UCB Biopharma SRLA Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa | 2026-12-21 |
| NCT06212999Phase 3Incyte CorporationA Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | 2026-12-26 |
| NCT06799000Phase 3Novartis PharmaceuticalsA Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1) | 2027-05-17 |
| NCT06840392Phase 3Novartis PharmaceuticalsA Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa | 2027-06-03 |
Add all 21 to your calendar (.ics) → With an account.
Among the 161 studies in Hidradenitis Suppurativa with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine whether IFX-1 is safe and effective in the treatment of moderate to severe hidradenitis suppurativa.
Hidradenitis suppurativa (HS) is a chronic devastating skin disorder affecting areas rich in apocrine glands. HS is diagnosed by its clinical features and its chronicity. It is recognized by the presence of recurrent, painful, deep-seated, rounded nodules usually ending in abscesses and sinus tracts with suppuration and hypertrophic scarring. As complement C5a is involved in the underlying acute inflammatory responses, this study is set up based on the hypothesis that IFX-1 might be able to block C5a induced pro-inflammatory effects such as neutrophil activation and cytokine generation, potentially contributing to the local skin inflammation and tissue damage.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Prior treatment with any of the following medications during the 28 days before Screening:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo
Drug: Placebo
Minimum Dose IFX-1 (400 mg Q4W)
Drug: IFX-1
Low dose IFX-1 (800 mg Q4W)
Drug: IFX-1
Medium Dose IFX-1 (800 mg Q2W)
Drug: IFX-1
High Dose IFX-1 (1200 mg Q2W)
Drug: IFX-1
Single IV infusions of IFX-1 diluted in sodium chloride.
Also known as: CaCP29, Vilobelimab
Placebo
Number of Patients With Hidradenitis Suppurativa Clinical Response (HiSCR) Determined at Week 16
The primary efficacy endpoint of the percentage of patients with HiSCR at Week 16 was analyzed using the multiple comparisons procedure-modelling (MCP-Mod) procedure. The definition for response to treatment based on HiSCR relative to Baseline was: at least 50% reduction in abscesses and inflammatory nodule (AN) count (over all anatomical regions) with no increase in number of abscesses and in number of draining fistulas.
Time frame: Week 16
Number of Patients With Hidradenitis Suppurativa Clinical Response (HiSCR) Determined at Week 12
Endpoint of the percentage of patients with HiSCR at Week 12 was analyzed in the same way as the primary endpoint using the MCP-Mod procedure and the same definition of response.
Time frame: Week 12
Number of Patients With Flares Relative to Day 1
The number of patients with flares analyzed in terms of ≥ 25% increase in abscess and inflammatory nodule (AN) count among patients with a minimum increase of 2 in AN count compared to Day 1 was analyzed by descriptive statistics by time point.
Time frame: From Day 1 until Day 309
Absolute Change in Modified Sartorius Score (mSS) From Day 1.
The absolute change from Day 1 will be analyzed by descriptive statistics by time point. The mSS is a summation of HS lesions based on a number of factors including anatomical region, number and type of lesions, distance between relevant lesions and lesions clearly separated by normal skin in each region measured as HS clinical parameters. The scale title for mSS is points. The mSS has a minimum value of 0 and no upper limit. The higher the score the more severe is the disease/worse is the outcome.
Time frame: From Day 1 until Day 309
Absolute Change in Patient's Global Assessment of Skin Pain From Day 1.
The absolute changes from baseline were analyzed by descriptive statistics by time point. The Numeric Rating Scale (NRS) was used to assess the worst skin pain due to HS. The scale title for the NRS is points. Ratings for this item range from a minimum of 0 points (no skin pain) to a maximum of 10 points (skin pain as bad as you can imagine). The higher the score the more severe the disease/worse is the outcome.
Time frame: From Day 1 until Day 309
Percentage of Patients Achieving NRS30
This is a segmented numeric version of the visual analog scale in which a respondent selects a whole number (0-10) that best reflects the intensity of their pain. The scale title for the NRS is points. The minimum score is 0 points (No skin pain), and the maximum score is 10 points (Skin pain as bad as you can imagine). The higher the score the more severe is the disease/worse is the outcome. The number of patients with at least 30% reduction and at least 1 point reduction from Day 1 in Patients Global Assessment of Skin Pain are displayed. The analysis is based on the worst skin pain the patients reported at the respective visits.
Time frame: From Day 1 until Day 309
Percentage of Patients Achieving NRS50.
This is a segmented numeric version of the visual analog scale in which a respondent selects a whole number (0-10) that best reflects the intensity of their pain. The scale title for NRS is points. The minimum score is 0 points (No skin pain), and the maximum score is 10 points (Skin pain as bad as you can imagine). The higher the score the more severe is the disease/worse is the outcome. The number of patients with at least 50% reduction and at least 1 point reduction from Day 1 in Patients Global Assessment of Skin Pain are displayed. The analysis is based on the worst skin pain the patients reported at the respective visits.
Time frame: From Day 1 until Day 309
Absolute Change in Dermatology Life Quality Index (DLQI) Score From Day 1.
The changes from Day 1 will be analyzed by descriptive statistics by time point. A score is documented for each of the 10 DLQI items, ranging from 0 to 3 for each item. The scale title for DLQI is points. The total score is the sum of the responses to all 10 DLQI items, ranging from the minimum of 0 points to the maximum of 30 points. A higher score corresponds to worse health related quality of life/outcome.
Time frame: From Day 1 until Day 309
Safety Parameters (Adverse Events) Will be Assessed.
The number of patients with any treatment emergent adverse event (adverse events that started after first infusion of IMP) was analyzed by time point.
Time frame: From Day 1 until Day 309
| Milestone | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | Cohort 5 |
|---|---|---|---|---|---|
| Started | 37 | 34 | 36 | 36 | 36 |
| Completed | 34 | 30 | 32 | 30 | 31 |
| Not completed | 3 | 4 | 4 | 6 | 5 |
| Milestone | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | Cohort 5 |
|---|---|---|---|---|---|
| Started | 0 | 0 | 72 | 84 | 0 |
| Number of patients in cohort 1 (main period) crossed over to cohort 3 or 4 | 0 | 0 | 16 | 18 | 0 |
| Number of patients in cohort 2 (main period) crossed over to cohort 3 or 4 | 0 | 0 | 12 | 18 | 0 |
| Number of patients in cohort 3 (main period) crossed over to cohort 3 or 4 | 0 | 0 | 17 | 15 | 0 |
| Number of patients in cohort 4 (main period) crossed over to cohort 3 or 4 | 0 | 0 | 12 | 18 | 0 |
| Number of patients in cohort 5 (main period) crossed over to cohort 3 or 4 | 0 | 0 | 15 | 16 | 0 |
| Completed | 0 | 0 | 67 | 54 | 0 |
| Not completed | 0 | 0 | 5 | 30 | 0 |
The primary efficacy endpoint of the percentage of patients with HiSCR at Week 16 was analyzed using the multiple comparisons procedure-modelling (MCP-Mod) procedure. The definition for response to treatment based on HiSCR relative to Baseline was: at least 50% reduction in abscesses and inflammatory nodule (AN) count (over all anatomical regions) with no increase in number of abscesses and in number of draining fistulas.
| Participants | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | Cohort 5 |
|---|---|---|---|---|---|
| HiSCR Responder | 16 | 12 | 17 | 12 | 15 |
| HiSCR Non-responder | 18 | 18 | 16 | 19 | 18 |
Endpoint of the percentage of patients with HiSCR at Week 12 was analyzed in the same way as the primary endpoint using the MCP-Mod procedure and the same definition of response.
| Participants | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | Cohort 5 |
|---|---|---|---|---|---|
| HiSCR Responder | 14 | 14 | 12 | 13 | 13 |
| HiSCR Non-responder | 20 | 17 | 21 | 19 | 19 |
The number of patients with flares analyzed in terms of ≥ 25% increase in abscess and inflammatory nodule (AN) count among patients with a minimum increase of 2 in AN count compared to Day 1 was analyzed by descriptive statistics by time point.
| Participants | Main Period: Cohort 1 | Main Period: Cohort 2 | Main Period: Cohort 3 | Main Period: Cohort 4 | Main Period: Cohort 5 | Extension Period: Cohort 3 | Extension Period: Cohort 4 |
|---|---|---|---|---|---|---|---|
| Patient with flares | 6 | 3 | 1 | 0 | 1 | 3 | 5 |
| Patient without flares | 28 | 27 | 31 | 30 | 31 | 64 | 47 |
The absolute change from Day 1 will be analyzed by descriptive statistics by time point. The mSS is a summation of HS lesions based on a number of factors including anatomical region, number and type of lesions, distance between relevant lesions and lesions clearly separated by normal skin in each region measured as HS clinical parameters. The scale title for mSS is points. The mSS has a minimum value of 0 and no upper limit. The higher the score the more severe is the disease/worse is the outcome.
| score on a scale | Main Period: Cohort 1 | Main Period: Cohort 2 | Main Period: Cohort 3 | Main Period: Cohort 4 | Main Period: Cohort 5 | Extension Period: Cohort 3 | Extension Period: Cohort 4 |
|---|---|---|---|---|---|---|---|
| Absolute Change in Modified Sartorius Score (mSS) From Day 1. | -16.4 ± 30.78 | -17.5 ± 48.43 | -29.4 ± 32.35 | -22.9 ± 52.00 | -35.2 ± 101.91 | -47.9 ± 70.87 | -27.5 ± 45.02 |
The absolute changes from baseline were analyzed by descriptive statistics by time point. The Numeric Rating Scale (NRS) was used to assess the worst skin pain due to HS. The scale title for the NRS is points. Ratings for this item range from a minimum of 0 points (no skin pain) to a maximum of 10 points (skin pain as bad as you can imagine). The higher the score the more severe the disease/worse is the outcome.
| score on a scale | Main Period: Cohort 1 | Main Period: Cohort 2 | Main Period: Cohort 3 | Main Period: Cohort 4 | Main Period: Cohort 5 | Extension Period: Cohort 3 | Extension Period: Cohort 4 |
|---|---|---|---|---|---|---|---|
| Absolute Change in Patient's Global Assessment of Skin Pain From Day 1. | -1.2 ± 2.82 | -0.1 ± 2.68 | -0.7 ± 2.37 | -1.5 ± 2.92 | -1.8 ± 3.03 | -1.5 ± 2.94 | -1.3 ± 2.52 |
This is a segmented numeric version of the visual analog scale in which a respondent selects a whole number (0-10) that best reflects the intensity of their pain. The scale title for the NRS is points. The minimum score is 0 points (No skin pain), and the maximum score is 10 points (Skin pain as bad as you can imagine). The higher the score the more severe is the disease/worse is the outcome. The number of patients with at least 30% reduction and at least 1 point reduction from Day 1 in Patients Global Assessment of Skin Pain are displayed. The analysis is based on the worst skin pain the patients reported at the respective visits.
| Participants | Main Period: Cohort 1 | Main Period: Cohort 2 | Main Period: Cohort 3 | Main Period: Cohort 4 | Main Period: Cohort 5 | Extension Period: Cohort 3 | Extension Period: Cohort 4 |
|---|---|---|---|---|---|---|---|
| Percentage of Patients Achieving NRS30 | 7 | 6 | 5 | 9 | 8 | 12 | 10 |
This is a segmented numeric version of the visual analog scale in which a respondent selects a whole number (0-10) that best reflects the intensity of their pain. The scale title for NRS is points. The minimum score is 0 points (No skin pain), and the maximum score is 10 points (Skin pain as bad as you can imagine). The higher the score the more severe is the disease/worse is the outcome. The number of patients with at least 50% reduction and at least 1 point reduction from Day 1 in Patients Global Assessment of Skin Pain are displayed. The analysis is based on the worst skin pain the patients reported at the respective visits.
| Participants | Main Period: Cohort 1 | Main Period: Cohort 2 | Main Period: Cohort 3 | Main Period: Cohort 4 | Main Period: Cohort 5 | Extension Period: Cohort 3 | Extension Period: Cohort 4 |
|---|---|---|---|---|---|---|---|
| Percentage of Patients Achieving NRS50. | 6 | 3 | 2 | 7 | 5 | 7 | 5 |
The changes from Day 1 will be analyzed by descriptive statistics by time point. A score is documented for each of the 10 DLQI items, ranging from 0 to 3 for each item. The scale title for DLQI is points. The total score is the sum of the responses to all 10 DLQI items, ranging from the minimum of 0 points to the maximum of 30 points. A higher score corresponds to worse health related quality of life/outcome.
| score on a scale | Main Period: Cohort 1 | Main Period: Cohort 2 | Main Period: Cohort 3 | Main Period: Cohort 4 | Main Period: Cohort 5 | Extension Period: Cohort 3 | Extension Period: Cohort 4 |
|---|---|---|---|---|---|---|---|
| Absolute Change in Dermatology Life Quality Index (DLQI) Score From Day 1. | -1.5 ± 6.11 | 0.6 ± 6.39 | -2.6 ± 7.19 | -5.0 ± 5.90 | -2.4 ± 5.24 | -1.5 ± 7.18 | -2.0 ± 6.52 |
The number of patients with any treatment emergent adverse event (adverse events that started after first infusion of IMP) was analyzed by time point.
| Participants | Main Period: Cohort 1 | Main Period: Cohort 2 | Main Period: Cohort 3 | Main Period: Cohort 4 | Main Period: Cohort 5 | Extension Period: Cohort 3 | Extension Period: Cohort 4 |
|---|---|---|---|---|---|---|---|
| Safety Parameters (Adverse Events) Will be Assessed. | 26 | 26 | 21 | 24 | 22 | 39 | 49 |
Collected over The observation period for Adverse Events (AEs) will start with confirmation of signed informed consent at Screening and ends at the Follow-up visit at Week 44.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Main Period: Cohort 1 | 0/36 (0%) | 0/36 (0%) | 26/36 (72.2%) |
| Main Period: Cohort 2 | 0/34 (0%) | 0/34 (0%) | 26/34 (76.5%) |
| Main Period: Cohort 3 | 0/35 (0%) | 1/35 (2.9%) | 21/35 (60%) |
| Main Period: Cohort 4 | 0/36 (0%) | 2/36 (5.6%) | 24/36 (66.7%) |
| Main Period: Cohort 5 | 0/36 (0%) | 3/36 (8.3%) | 22/36 (61.1%) |
| Extension Period: Cohort 3 | 0/72 (0%) | 2/72 (2.8%) | 34/72 (47.2%) |
| Extension Period: Cohort 4 | 0/84 (0%) | 3/84 (3.6%) | 49/84 (58.3%) |
| Event | Main Period: Cohort 1 | Main Period: Cohort 2 | Main Period: Cohort 3 | Main Period: Cohort 4 | Main Period: Cohort 5 | Extension Period: Cohort 3 | Extension Period: Cohort 4 |
|---|---|---|---|---|---|---|---|
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/36 | 0/34 | 1/35 | 0/36 | 0/36 | 0/72 | 0/84 |
| Abscess bacterialInfections and infestations | 0/36 | 0/34 | 0/35 | 1/36 | 0/36 | 0/72 | 0/84 |
| PneumoniaInfections and infestations | 0/36 | 0/34 | 0/35 | 0/36 | 1/36 | 0/72 | 0/84 |
| SepsisInfections and infestations | 0/36 | 0/34 | 0/35 | 1/36 | 0/36 | 0/72 | 0/84 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 0/36 | 0/34 | 0/35 | 0/36 | 1/36 | 0/72 | 0/84 |
| HidradenitisSkin and subcutaneous tissue disorders | 0/36 | 0/34 | 0/35 | 0/36 | 1/36 | 0/72 | 2/84 |
| Bile duct stoneHepatobiliary disorders | 0/36 | 0/34 | 0/35 | 0/36 | 0/36 | 1/72 | 0/84 |
| Cholangitis infectiveInfections and infestations | 0/36 | 0/34 | 0/35 | 0/36 | 0/36 | 1/72 | 0/84 |
| Femoral neck fractureInjury, poisoning and procedural complications | 0/36 | 0/34 | 0/35 | 0/36 | 0/36 | 1/72 | 0/84 |
| SciaticaNervous system disorders | 0/36 | 0/34 | 0/35 | 0/36 | 0/36 | 1/72 | 0/84 |
| Event | Main Period: Cohort 1 | Main Period: Cohort 2 | Main Period: Cohort 3 | Main Period: Cohort 4 | Main Period: Cohort 5 | Extension Period: Cohort 3 | Extension Period: Cohort 4 |
|---|---|---|---|---|---|---|---|
| HidradenitisSkin and subcutaneous tissue disorders | 5/36 | 4/34 | 2/35 | 7/36 | 6/36 | 8/72 | 10/84 |
| NasopharyngitisInfections and infestations | 6/36 | 4/34 | 6/35 | 4/36 | 3/36 | 4/72 | 8/84 |
| HeadacheNervous system disorders | 6/36 | 4/34 | 0/35 | 4/36 | 5/36 | 4/72 | 6/84 |
| DiarrhoeaGastrointestinal disorders | 0/36 | 4/34 | 2/35 | 3/36 | 1/36 | 2/72 | 2/84 |
| Pain of skinSkin and subcutaneous tissue disorders | 0/36 | 3/34 | 1/35 | 0/36 | 0/36 | 1/72 | 1/84 |
| FatigueGeneral disorders | 2/36 | 0/34 | 3/35 | 2/36 | 3/36 | 0/72 | 1/84 |
| InfluenzaInfections and infestations | 2/36 | 0/34 | 0/35 | 0/36 | 3/36 | 2/72 | 2/84 |
| NauseaGastrointestinal disorders | 2/36 | 2/34 | 1/35 | 1/36 | 2/36 | 0/72 | 2/84 |
| Viral upper respiratory tract infectionInfections and infestations | 0/36 | 2/34 | 0/35 | 0/36 | 0/36 | 0/72 | 0/84 |
| PyrexiaGeneral disorders | 1/36 | 2/34 | 0/35 | 0/36 | 2/36 | 2/72 | 0/84 |
Baseline analysis performed for safety analysis set (SAS)
| Age, Categorical(Participants) | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | Cohort 5 | Total |
|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 35 | 33 | 35 | 36 | 35 | 174 |
| >=65 years | 1 | 1 | 0 | 0 | 1 | 3 |
| Age, Continuous(years) | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | Cohort 5 | Total |
|---|---|---|---|---|---|---|
| Median | 34.5 (27.0 to 42.5) | 39.0 (33.0 to 45.0) | 35.0 (25.0 to 46.0) | 37.0 (31.0 to 46.0) | 33.5 (27.5 to 41.0) | 36.0 (29.0 to 45.0) |
| Sex: Female, Male(Participants) | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | Cohort 5 | Total |
|---|---|---|---|---|---|---|
| Female | 21 | 16 | 18 | 20 | 23 | 98 |
| Male | 15 | 18 | 17 | 16 | 13 | 79 |
| Ethnicity (NIH/OMB)(Participants) | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | Cohort 5 | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 1 | 1 | 1 | 4 | 7 |
| Not Hispanic or Latino | 36 | 33 | 34 | 35 | 32 | 170 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | Cohort 5 | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 1 | 1 |
| Asian | 0 | 1 | 0 | 0 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 3 | 2 | 4 | 4 | 4 | 17 |
| White | 33 | 31 | 29 | 32 | 27 | 152 |
| More than one race | 0 | 0 | 1 | 0 | 1 | 2 |
| Unknown or Not Reported | 0 | 0 | 1 | 0 | 3 | 4 |
| Region of Enrollment(Participants) | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | Cohort 5 | Total |
|---|---|---|---|---|---|---|
| Greece | 9 | 5 | 9 | 10 | 14 | 47 |
| Canada | 1 | 0 | 2 | 4 | 1 | 8 |
| Netherlands | 2 | 0 | 1 | 1 | 2 | 6 |
| United States | 4 | 7 | 8 | 7 | 7 | 33 |
| Denmark | 2 | 2 | 1 | 0 | 0 | 5 |
| Poland | 11 | 9 | 4 | 8 | 6 | 38 |
| Bulgaria | 2 | 4 | 2 | 1 | 0 | 9 |
| France | 4 | 3 | 5 | 3 | 4 | 19 |
| Germany | 1 | 4 | 3 | 2 | 2 | 12 |
| Baseline AN (total abscess and inflammatory nodule) count(lesions) | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | Cohort 5 | Total |
|---|---|---|---|---|---|---|
| Median | 9.5 (5.0 to 15.0) | 9.0 (6.0 to 15.0) | 8.0 (7.0 to 17.0) | 10.0 (6.0 to 16.0) | 12.5 (5.5 to 15.5) | 9.0 (6.0 to 16.0) |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Feb 2018 to primary completion in May 2019, 15 months.
Results were first posted in Apr 2021, 1 year 10 months after primary completion.
Of 44 industry-sponsored phase 2 interventional studies under Hidradenitis Suppurativa, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 23. This study's 15 months is close to that.
Counting every sponsor, half of 54 studies reached it within 15 months; a quarter within 11 and three quarters within 24.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vilobelimab
InflaRx GmbH